- Home
- VGI vs QNCX Comparison
VGI vs QNCX Comparison
Compare VGI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | QNCX |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 139.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VGI | QNCX |
|---|---|---|
| Price | $7.86 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 46.0K | ★ 808.9K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $0.72 |
| 52 Week High | $7.99 | $4.55 |
Technical Indicators
Market Signals| Indicator | VGI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 49.75 |
| Support Level | $7.78 | $3.18 |
| Resistance Level | $7.87 | $3.80 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 51.16 | 10.23 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.